(MedPage Today) — AURORA, Colo. — Atosiban, an oxytocin receptor antagonist available in Europe, was not superior to placebo in improving neonatal outcomes for threatened preterm birth between 30 and 34 weeks’ gestation, according to the APOSTEL…
Source link : https://www.medpagetoday.com/meetingcoverage/smfm/114040
Author :
Publish date : 2025-01-31 21:16:39
Copyright for syndicated content belongs to the linked Source.
